These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 36198179)

  • 21. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy.
    Eftimov F; Winer JB; Vermeulen M; de Haan R; van Schaik IN
    Cochrane Database Syst Rev; 2013 Dec; (12):CD001797. PubMed ID: 24379104
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase 3, multicentre, randomised, double-blind, placebo-controlled, parallel-group study of ustekinumab in Japanese patients with active polymyositis and dermatomyositis who have not adequately responded to one or more standard-of-care treatments.
    Kawahata K; Ishii T; Gono T; Tsuchiya Y; Ohashi H; Yoshizawa K; Zheng R; Ayabe M; Nishikawa K
    RMD Open; 2023 Aug; 9(3):. PubMed ID: 37652554
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial.
    Wolinsky JS; Arnold DL; Brochet B; Hartung HP; Montalban X; Naismith RT; Manfrini M; Overell J; Koendgen H; Sauter A; Bennett I; Hubeaux S; Kappos L; Hauser SL
    Lancet Neurol; 2020 Dec; 19(12):998-1009. PubMed ID: 33129442
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder.
    Nasser A; Hull JT; Chaturvedi SA; Liranso T; Odebo O; Kosheleff AR; Fry N; Cutler AJ; Rubin J; Schwabe S; Childress A
    CNS Drugs; 2022 Aug; 36(8):897-915. PubMed ID: 35896943
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intravenous immunoglobulin for presumed viral myocarditis in children and adults.
    Robinson J; Hartling L; Vandermeer B; Sebastianski M; Klassen TP
    Cochrane Database Syst Rev; 2020 Aug; 8(8):CD004370. PubMed ID: 32835416
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study.
    Hahn AF; Bolton CF; Zochodne D; Feasby TE
    Brain; 1996 Aug; 119 ( Pt 4)():1067-77. PubMed ID: 8813271
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intravenous immunoglobulins as first-line treatment in idiopathic inflammatory myopathies: a pilot study.
    Lim J; Eftimov F; Verhamme C; Brusse E; Hoogendijk JE; Saris CGJ; Raaphorst J; De Haan RJ; van Schaik IN; Aronica E; de Visser M; van der Kooi AJ
    Rheumatology (Oxford); 2021 Apr; 60(4):1784-1792. PubMed ID: 33099648
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Don't Fear the Reefer-Evidence Mounts for Plant-Based Cannabidiol as Treatment for Epilepsy.
    Perry MS
    Epilepsy Curr; 2019; 19(2):93-95. PubMed ID: 30955420
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial.
    Hughes RA; Donofrio P; Bril V; Dalakas MC; Deng C; Hanna K; Hartung HP; Latov N; Merkies IS; van Doorn PA;
    Lancet Neurol; 2008 Feb; 7(2):136-44. PubMed ID: 18178525
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and tolerability of immune globulin intravenous in chronic inflammatory demyelinating polyradiculoneuropathy.
    Donofrio PD; Bril V; Dalakas MC; Deng C; Hanna K; Hartung HP; Hughes R; Latov N; Merkies I; van Doorn P;
    Arch Neurol; 2010 Sep; 67(9):1082-8. PubMed ID: 20837852
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials.
    Kahaly GJ; Douglas RS; Holt RJ; Sile S; Smith TJ
    Lancet Diabetes Endocrinol; 2021 Jun; 9(6):360-372. PubMed ID: 33865501
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment with high-dose recombinant human hyaluronidase-facilitated subcutaneous immune globulins in patients with juvenile dermatomyositis who are intolerant to intravenous immune globulins: a report of 5 cases.
    Speth F; Haas JP; Hinze CH
    Pediatr Rheumatol Online J; 2016 Sep; 14(1):52. PubMed ID: 27623619
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intravenous immunoglobulin therapy in adult patients with polymyositis/dermatomyositis: a systematic literature review.
    Wang DX; Shu XM; Tian XL; Chen F; Zu N; Ma L; Wang GC
    Clin Rheumatol; 2012 May; 31(5):801-6. PubMed ID: 22274797
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients.
    Cherin P; Herson S; Wechsler B; Piette JC; Bletry O; Coutellier A; Ziza JM; Godeau P
    Am J Med; 1991 Aug; 91(2):162-8. PubMed ID: 1714235
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interventions for necrotizing soft tissue infections in adults.
    Hua C; Bosc R; Sbidian E; De Prost N; Hughes C; Jabre P; Chosidow O; Le Cleach L
    Cochrane Database Syst Rev; 2018 May; 5(5):CD011680. PubMed ID: 29851032
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Controlled studies with high-dose intravenous immunoglobulin in the treatment of dermatomyositis, inclusion body myositis, and polymyositis.
    Dalakas MC
    Neurology; 1998 Dec; 51(6 Suppl 5):S37-45. PubMed ID: 9851729
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intravenous immunoglobulin for Guillain-Barré syndrome.
    Hughes RA; Swan AV; van Doorn PA
    Cochrane Database Syst Rev; 2014 Sep; 2014(9):CD002063. PubMed ID: 25238327
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A multicenter, randomized, double-blind, placebo-controlled trial of high-dose intravenous immunoglobulin for oral corticosteroid-dependent asthma.
    Kishiyama JL; Valacer D; Cunningham-Rundles C; Sperber K; Richmond GW; Abramson S; Glovsky M; Stiehm R; Stocks J; Rosenberg L; Shames RS; Corn B; Shearer WT; Bacot B; DiMaio M; Tonetta S; Adelman DC
    Clin Immunol; 1999 May; 91(2):126-33. PubMed ID: 10227804
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis: A Phase 2b Randomized Clinical Trial.
    Guttman-Yassky E; Blauvelt A; Eichenfield LF; Paller AS; Armstrong AW; Drew J; Gopalan R; Simpson EL
    JAMA Dermatol; 2020 Apr; 156(4):411-420. PubMed ID: 32101256
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.